Related Experiment Video

Updated: Dec 29, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

811

Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies

Andrew J Haak1, Merrick T Ducharme1, Ana M Diaz Espinosa1

  • 1Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.

Trends in Pharmacological Sciences
|February 4, 2020
PubMed

Insights

G protein-coupled receptors (GPCRs) play a dual role in pulmonary fibrosis. Targeting GPCRs offers a promising avenue for developing novel therapies for idiopathic pulmonary fibrosis (IPF).

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Cell Biology

Background:

  • G protein-coupled receptors (GPCRs) are implicated in pulmonary fibrosis pathogenesis via profibrotic fibroblast activation.
  • Conversely, Gαs-coupled GPCRs demonstrate beneficial effects by reducing fibroblast activation and fibrosis.

Purpose of the Study:

  • To review how fibrosis-promoting and -inhibiting GPCR signaling converge on downstream effectors.
  • To discuss challenges in identifying effective idiopathic pulmonary fibrosis (IPF) therapies due to GPCR expression dynamics.
  • To explore next-generation strategies for GPCR-targeted pulmonary fibrosis therapies.

Main Methods:

  • Literature review of GPCR signaling in pulmonary fibrosis.
  • Analysis of downstream signaling and transcriptional effectors.
  • Discussion of therapeutic strategies including target selection, polypharmacology, and personalized medicine.

Main Results:

  • GPCR signaling pathways involved in promoting and inhibiting pulmonary fibrosis have been identified.
  • GPCR expression diversity and dynamics present significant challenges for therapeutic development in IPF.
  • Next-generation strategies offer potential for more effective GPCR-targeted treatments.

Conclusions:

  • Understanding the complex GPCR signaling network is crucial for pulmonary fibrosis treatment.
  • Novel therapeutic approaches are needed to overcome challenges in targeting GPCRs for IPF.
  • Personalized medicine and polypharmacology show promise for future GPCR-based therapies for pulmonary fibrosis.
Keywords:
G protein-coupled receptorMRTFROCKTAZYAPfibrosis

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.4K
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

763

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
382
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
390
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.1K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
3.7K